Your Health, We Care
Release date: 2024-08-14 17:25:19 Recommended: 129
Venetoclax is a novel BCL-2 inhibitor that induces apoptosis in cancer cells by binding to the BCL-2 protein. Venetoclax is widely used in the treatment of hematological malignancies such as CLL, SLL and AML.
When venetoclax is used with a strong or moderate CYP3A inhibitor or a P-gp inhibitor, it significantly increases the maximum plasma concentration (Cmax) and drug exposure (AUC0-INF) of venetoclax.
This increase may lead to increased toxicity with venetoclax, including a higher risk of tumor lysis syndrome (TLS), a potentially serious complication. Extreme caution is required when combining these drugs, and the dose or frequency of venetoclax may need to be adjusted.
Patients with acute myeloid leukemia (AML) usually start on day 1 of Cycle 1 with a gradual increase in the dose of venetoclax. 100 mg daily on day 1, 200 mg daily on day 2, and 400 mg daily on day 3. From day 4 onwards, patients will continue to receive 400 mg daily in combination with azacitidine or decitabine every 28 days. The other regimen is 600 mg daily in combination with low-dose cytarabine.
Lucius Pharmaceuticals is committed to scientific and technological innovation and is equipped with industry-leading pharmaceutical equipment. These machines are highly automated and intelligent, making every step of pharmaceutical production precise and efficient. From raw material screening to finished product packaging, all processes are closely monitored to ensure product quality and consistency.
Adhering to the principle of putting the health and safety of patients first, Lucius Pharmaceuticals has established a comprehensive quality management system in strict compliance with international quality management system standards. Whether it is raw material procurement, production process, storage and sales, every link is strictly monitored and tested. Through continuous technological innovation and quality improvement, Lucius Pharmaceuticals is committed to providing the highest standards of medicines and being your trusted guardian of health.
[Warm tips] The above venetoclax dosage is determined based on the results of current scientific research and clinical trials, and the specific treatment plan and dosage should be personalized by the doctor according to the specific situation of the patient.
